Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder

BACKGROUND: Epstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Nan, Wang, Na, Zhang, Peiling, Wang, Gaoxiang, Mao, Xia, Peng, Dan, Kuang, Dong, Chen, Liting, Zhu, Li, Zhou, Jianfeng, Zhang, Yicheng, Cao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339712/
https://www.ncbi.nlm.nih.gov/pubmed/34367995
http://dx.doi.org/10.3389/fonc.2021.709370
_version_ 1783733648915169280
author Yan, Nan
Wang, Na
Zhang, Peiling
Wang, Gaoxiang
Mao, Xia
Peng, Dan
Kuang, Dong
Chen, Liting
Zhu, Li
Zhou, Jianfeng
Zhang, Yicheng
Cao, Yang
author_facet Yan, Nan
Wang, Na
Zhang, Peiling
Wang, Gaoxiang
Mao, Xia
Peng, Dan
Kuang, Dong
Chen, Liting
Zhu, Li
Zhou, Jianfeng
Zhang, Yicheng
Cao, Yang
author_sort Yan, Nan
collection PubMed
description BACKGROUND: Epstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation and PTLD. However, reports on the curative management of refractory PTLD are scarce. CASE PRESENTATION: In this report, we describe the successful management of two patients with EBV-PTLD with chimeric antigen receptor T-cell (CAR-T) therapy. CONCLUSION: The present results demonstrated that patients with EBV-PTLD may benefit from CAR-T therapy and that the toxicity is manageable. Further studies are needed to verify these findings.
format Online
Article
Text
id pubmed-8339712
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83397122021-08-06 Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder Yan, Nan Wang, Na Zhang, Peiling Wang, Gaoxiang Mao, Xia Peng, Dan Kuang, Dong Chen, Liting Zhu, Li Zhou, Jianfeng Zhang, Yicheng Cao, Yang Front Oncol Oncology BACKGROUND: Epstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation and PTLD. However, reports on the curative management of refractory PTLD are scarce. CASE PRESENTATION: In this report, we describe the successful management of two patients with EBV-PTLD with chimeric antigen receptor T-cell (CAR-T) therapy. CONCLUSION: The present results demonstrated that patients with EBV-PTLD may benefit from CAR-T therapy and that the toxicity is manageable. Further studies are needed to verify these findings. Frontiers Media S.A. 2021-07-22 /pmc/articles/PMC8339712/ /pubmed/34367995 http://dx.doi.org/10.3389/fonc.2021.709370 Text en Copyright © 2021 Yan, Wang, Zhang, Wang, Mao, Peng, Kuang, Chen, Zhu, Zhou, Zhang and Cao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yan, Nan
Wang, Na
Zhang, Peiling
Wang, Gaoxiang
Mao, Xia
Peng, Dan
Kuang, Dong
Chen, Liting
Zhu, Li
Zhou, Jianfeng
Zhang, Yicheng
Cao, Yang
Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
title Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
title_full Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
title_fullStr Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
title_full_unstemmed Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
title_short Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
title_sort case report: successful chimeric antigen receptor t cell therapy in haploidentical-allogeneic stem cell transplant patients with post-transplant lymphoproliferative disorder
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339712/
https://www.ncbi.nlm.nih.gov/pubmed/34367995
http://dx.doi.org/10.3389/fonc.2021.709370
work_keys_str_mv AT yannan casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT wangna casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT zhangpeiling casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT wanggaoxiang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT maoxia casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT pengdan casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT kuangdong casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT chenliting casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT zhuli casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT zhoujianfeng casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT zhangyicheng casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder
AT caoyang casereportsuccessfulchimericantigenreceptortcelltherapyinhaploidenticalallogeneicstemcelltransplantpatientswithposttransplantlymphoproliferativedisorder

Ejemplares similares